Proteoform Signatures of Cardiac Dysfunction

Abstract

Cardiac dysfunction encompasses a spectrum of pathologies that manifest as compromised myocardial performance and is a leading cause of morbidity and mortality globally. Recent advances in proteomics have enabled the detailed characterization of proteoforms—protein variants resulting from genetic variation, alternative splicing, and post-translational modifications—in cardiac tissues and circulation. These proteoform signatures provide mechanistic insights into the molecular underpinnings of cardiac dysfunction and hold promise as biomarkers for diagnosis, risk stratification, and therapeutic monitoring. This review synthesizes current evidence on proteoform signatures related to cardiac dysfunction, emphasizing their pathophysiological relevance, clinical utility, and future potential in precision cardiology.

Introduction

Cardiac dysfunction, including heart failure, arrhythmias, and other myocardial pathologies, represents a significant clinical challenge. The molecular complexity of cardiac diseases often impedes precise diagnosis and management using traditional clinical and biochemical tools. The advent of high-resolution mass spectrometry and advanced proteomics has enabled the identification and quantification of proteoforms—distinct molecular entities of proteins that arise due to genetic variation, alternative splicing, and diverse post-translational modifications such as phosphorylation, acetylation, and glycosylation. Proteoform signatures reflect cellular states and disease processes at an unprecedented resolution, offering new avenues for the assessment and management of cardiac disorders. This article explores the clinical significance of proteoform signatures in cardiac dysfunction, from epidemiology and pathophysiology to diagnosis and emerging therapies.

Epidemiology / Disease Burden

Cardiac dysfunction, particularly heart failure, impacts over 26 million people worldwide, with rising prevalence due to aging populations and improved survival from acute cardiac events. Conventional risk prediction tools, although valuable, often fall short in capturing the molecular intricacies underlying disease progression. Proteoform profiling has revealed unique molecular fingerprints that correlate with disease severity and outcomes, suggesting a potential to refine epidemiological understanding and facilitate early detection strategies. Recent population-based studies integrating proteomics have started to delineate proteoform patterns associated with incident cardiac dysfunction, providing a more granular view of disease burden and heterogeneity.

Pathophysiology

The pathophysiology of cardiac dysfunction is multifaceted, involving alterations in myocardial contractility, electrical conduction, neurohormonal regulation, and cellular viability. Proteoforms play critical roles in these processes. For instance, differential phosphorylation of cardiac troponins modulates calcium sensitivity and contractile function, while oxidative modifications of sarcomeric and mitochondrial proteins contribute to impaired energy metabolism and apoptosis. Proteoform analysis has elucidated disease-specific patterns, such as the accumulation of hyperphosphorylated myofilament proteins in heart failure with reduced ejection fraction and distinct glycoforms of natriuretic peptides in diastolic dysfunction. These molecular signatures offer mechanistic explanations for phenotypic variability and therapeutic response.

Risk Factors

Traditional risk factors for cardiac dysfunction include hypertension, diabetes mellitus, ischemic heart disease, and genetic predisposition. Proteoform signatures can reveal the molecular impact of these risk factors before clinical manifestations arise. For example, individuals with poorly controlled diabetes exhibit proteoform changes in plasma proteins related to inflammation and oxidative stress, preceding detectable cardiac dysfunction. Similarly, familial cardiomyopathies display unique proteoform alterations in sarcomeric proteins, providing early markers of disease risk and progression. Integration of proteoform data with clinical risk models may enable personalized risk assessment and targeted preventive strategies.

Clinical Features

Cardiac dysfunction presents with a spectrum of clinical features, ranging from asymptomatic ventricular dysfunction to overt heart failure, arrhythmias, and sudden cardiac death. Proteoform analyses of cardiac troponins, natriuretic peptides, and extracellular matrix proteins have demonstrated improved discrimination between heart failure phenotypes and etiologies compared to traditional biomarkers. For instance, specific post-translationally modified forms of troponin I are more closely associated with acute myocardial injury, while distinct glycoforms of BNP better reflect the chronicity and severity of heart failure. These findings highlight the potential of proteoform signatures to enhance diagnostic accuracy and guide tailored therapy.

Diagnosis

The diagnostic landscape for cardiac dysfunction has evolved with the incorporation of high-sensitivity assays for conventional biomarkers. However, the heterogeneity of proteoform profiles in cardiac pathologies offers an opportunity for further refinement. Mass spectrometry-based proteomics enables comprehensive identification and quantification of cardiac-specific proteoforms in tissue and blood samples. Recent studies have shown that proteoform signatures can differentiate between ischemic and non-ischemic heart failure, stratify patients by risk of adverse outcomes, and predict response to specific therapies. These advances have the potential to transform diagnostic workflows, moving toward precision medicine in cardiology.

Treatment & Management

Current management of cardiac dysfunction relies on guideline-directed medical therapy, device implantation, and lifestyle modification. Proteoform signatures may inform treatment selection and monitoring by elucidating molecular mechanisms underlying variable therapeutic responses. For example, patients with heart failure who exhibit persistent proteoform alterations despite optimal therapy may benefit from advanced interventions or novel agents. Furthermore, proteoform-based monitoring can facilitate early detection of treatment-related toxicity or disease progression, enabling timely adjustments in management. Integration of proteoform data with clinical and imaging findings may enhance multidisciplinary care and improve patient outcomes.

Recent Advances / Emerging Therapies

Emerging proteomics technologies continue to expand our understanding of cardiac disease biology. Single-cell proteomics and advanced mass spectrometric techniques allow for deep profiling of proteoforms at the cellular and tissue level. Novel therapeutic strategies targeting specific proteoforms, such as small molecules or monoclonal antibodies, are under investigation for the treatment of heart failure and arrhythmias. Additionally, machine learning approaches applied to proteoform datasets have shown promise in predicting clinical trajectories and identifying novel therapeutic targets. These advances are paving the way for personalized medicine approaches in cardiology.

Guideline Recommendations

While current clinical guidelines emphasize the use of established biomarkers such as troponin and natriuretic peptides, there is increasing recognition of the potential value of proteoform signatures. Major cardiology societies advocate for ongoing research and validation of novel biomarkers, including proteoforms, in large, well-characterized cohorts. The integration of proteoform profiling into routine practice awaits further evidence from prospective studies demonstrating clinical utility, cost-effectiveness, and improvement in patient-centered outcomes. Nevertheless, early adoption in specialized centers and research settings is accelerating the translation of proteoform science into clinical cardiology.

Conclusion

Proteoform signatures offer a transformative approach to understanding and managing cardiac dysfunction. By elucidating the molecular heterogeneity underlying clinical phenotypes, proteoform analysis provides novel insights into disease mechanisms, enhances risk stratification, and supports the development of precision diagnostics and targeted therapies. Ongoing advances in proteomics technology and bioinformatics will undoubtedly refine our ability to leverage proteoform data for improved patient care. As evidence accumulates, the integration of proteoform signatures into clinical practice promises to usher in a new era of personalized cardiology, with the potential to significantly impact outcomes for patients with cardiac dysfunction.